WallStSmart

Merck & Company Inc (MRK)vsUFP Technologies Inc (UFPT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 10439% more annual revenue ($66.57B vs $631.64M). UFPT leads profitability with a 11.5% profit margin vs 4.8%. MRK appears more attractively valued with a PEG of 2.64. UFPT earns a higher WallStSmart Score of 60/100 (C+).

MRK

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27

UFPT

Buy

60

out of 100

Grade: C+

Growth: 8.0Profit: 7.5Value: 3.7Quality: 8.5
Piotroski: 5/9Altman Z: 3.43
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-73.7%)

Margin of Safety

-73.7%

Fair Value

$82.84

Current Price

$143.93

$61.09 premium

UndervaluedFair: $82.84Overvalued

Intrinsic value data unavailable for UFPT.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK2 strengths · Avg: 9.0/10
Market CapQuality
$355.10B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

UFPT4 strengths · Avg: 8.8/10
Altman Z-ScoreHealth
3.4310/10

Safe zone — low bankruptcy risk

Debt/EquityHealth
0.299/10

Conservative balance sheet, low leverage

Revenue GrowthGrowth
15.1%8/10

15.1% revenue growth

EPS GrowthGrowth
21.3%8/10

Earnings expanding 21.3% YoY

Areas to Watch

MRK4 concerns · Avg: 3.3/10
Price/BookValuation
8.5x4/10

Trading at 8.5x book value

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Debt/EquityHealth
1.293/10

Elevated debt levels

UFPT2 concerns · Avg: 3.0/10
P/E RatioValuation
30.1x4/10

Premium valuation, high expectations priced in

PEG RatioValuation
3.802/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Free Cash Flow.

Bull Case : UFPT

The strongest argument for UFPT centers on Altman Z-Score, Debt/Equity, Revenue Growth. Revenue growth of 15.1% demonstrates continued momentum.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.

Bear Case : UFPT

The primary concerns for UFPT are P/E Ratio, PEG Ratio.

Key Dynamics to Monitor

MRK profiles as a value stock while UFPT is a growth play — different risk/reward profiles.

UFPT carries more volatility with a beta of 1.07 — expect wider price swings.

UFPT is growing revenue faster at 15.1% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Bottom Line

UFPT scores higher overall (60/100 vs 36/100) and 15.1% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

UFP Technologies Inc

HEALTHCARE · MEDICAL DEVICES · USA

UFP Technologies, Inc. designs and converts foams, films and plastic materials for the medical, automotive, consumer, electronic, industrial, aerospace and defense markets in the United States. The company is headquartered in Newburyport, Massachusetts.

Want to dig deeper into these stocks?